HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reduced serum caeruloplasmin levels in non-wilsonian movement disorders.

Abstract
Reduction in caeruloplasmin (Cp) levels is sometimes found in other sporadic movement disorders, not limited to Wilson's disease (WD). Serum levels of Cp, copper, iron and gamma-glutamyl transpeptidase were measured in 71 patients with various diagnoses of movement disorders, including Parkinson's disease (PD), atypical parkinsonian disorders, tardive dyskinesia, essential tremor, and idiopathic focal dystonia, and compared with those of 26 healthy age- and gender-matched controls. The mean Cp level in the patient group was 20.5 ± 4.2 mg/dl , lower than in controls (23.5 ± 7.2 mg/dl; p = 0.005). In subgroup analysis, mean Cp level of PD patients (19.6 ± 3.0 mg/dl) was lower than that of controls (p = 0.045). In a group analysis as neurodegenerative movement disorders (NDD), their mean Cp level was 19.9 ± 3.0 mg/dl, lower than that of controls (p = 0.019). Linear regression analysis indicated that the presence of NDD was the main factor associated with lower Cp levels. The finding of reduced serum Cp level in non-Wilsonian movement disorders and selective reduction in the neurodegenerative subgroup supports the notion that Cp might be associated with the cascade of neurotoxicity in NDD. The variation in Cp level in other non-WD conditions highlights the fact that Cp level is a poor screening test for WD in the absence of clear clinical suspicion.
AuthorsHelen Ling, Roongroj Bhidayasiri
JournalEuropean neurology (Eur Neurol) Vol. 66 Issue 3 Pg. 123-7 ( 2011) ISSN: 1421-9913 [Electronic] Switzerland
PMID21865760 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 S. Karger AG, Basel.
Chemical References
  • Antiparkinson Agents
  • Levodopa
  • Ceruloplasmin
Topics
  • Adult
  • Analysis of Variance
  • Antiparkinson Agents (therapeutic use)
  • Case-Control Studies
  • Ceruloplasmin (metabolism)
  • Female
  • Humans
  • Levodopa (therapeutic use)
  • Male
  • Middle Aged
  • Movement Disorders (blood, classification)
  • Parkinson Disease (blood, drug therapy)
  • Regression Analysis
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: